NCT07073170

Brief Summary

The main purpose of this study is to investigate LY3549492 in Chinese participants with type 2 diabetes. Participation in the study will last about 18 weeks.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
36

participants targeted

Target at P50-P75 for phase_1 type-2-diabetes

Timeline
Completed

Started Jul 2025

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 10, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 18, 2025

Completed
7 days until next milestone

Study Start

First participant enrolled

July 25, 2025

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 27, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 27, 2026

Completed
Last Updated

March 3, 2026

Status Verified

March 1, 2026

Enrollment Period

6 months

First QC Date

July 10, 2025

Last Update Submit

March 2, 2026

Conditions

Type 2 Diabetes

Outcome Measures

Primary Outcomes (1)

  • Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration

    A summary of treatment emergent adverse events (TEAEs), SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.

    Baseline through Week 14

Secondary Outcomes (2)

  • Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3549492

    Predose through Week 13

  • PK: Area Under the Concentration Versus Time Curve (AUC) of LY3549492

    Predose through Week 13

Study Arms (4)

LY3549492 Dose 1

EXPERIMENTAL

Participants will receive LY3549492 orally

Drug: LY3549492

LY3549492 Dose 2

EXPERIMENTAL

Participants will receive LY3549492 orally

Drug: LY3549492

LY3549492 Dose 3

EXPERIMENTAL

Participants will receive LY3549492 orally

Drug: LY3549492

Placebo

PLACEBO COMPARATOR

Participants will receive Placebo orally

Drug: Placebo

Interventions

LY3549492DRUG

Administered orally

LY3549492 Dose 1LY3549492 Dose 2LY3549492 Dose 3
PlaceboDRUG

Administered orally

Placebo

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Are native Chinese
  • Have type 2 diabetes for at least 6 months
  • Have been treated with diet and exercise, with or without a stable dose of metformin for at least 3 months
  • Have hemoglobin A1c (HbA1c) of at least 7% and no greater than 10%
  • Have a body mass index (BMI) of at least 20 milligrams per square meter (kg/m2) and no greater than 40 kg/m2
  • Have had a stable body weight for the 3 months prior to screening
  • Women must not be of childbearing potential

You may not qualify if:

  • Have type 1 diabetes or have had an episode of ketoacidosis or hyperosmolar state requiring hospitalization
  • Have had an episode of severe hypoglycemia within 6 months or have a history of hypoglycemia unawareness
  • Have a clinically significant gastric emptying abnormality
  • Have or have a history of pancreatitis
  • Have signs and symptoms of liver disease, with the exception of non-alcoholic fatty liver disease
  • Have a personal or family history of multiple endocrine neoplasia syndrome type 2 or medullary thyroid carcinoma
  • Have an uncontrolled endocrine abnormality
  • Have an abnormal blood pressure or pulse rate
  • Have a 12-lead electrocardiogram (ECG) abnormality
  • Have a significant history within the past 6 months or current evidence of comorbidities capable of altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study intervention, or of interfering with the interpretation of data

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Peking University People's Hospital

Beijing, 100033, China

Location

West China Hospital of Sichuan University

Chengdu, 610041, China

Location

Peking University First Hospital

Dongcheng District, 100009, China

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)

    Eli Lilly and Company

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 10, 2025

First Posted

July 18, 2025

Study Start

July 25, 2025

Primary Completion

January 27, 2026

Study Completion

January 27, 2026

Last Updated

March 3, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Locations

CN(3)